Correction: Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study).
APA
Kawakami H, Nakanishi K, et al. (2025). Correction: Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study).. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 28(1), 62. https://doi.org/10.1007/s10120-024-01570-x
MLA
Kawakami H, et al.. "Correction: Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study).." Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, vol. 28, no. 1, 2025, pp. 62.
PMID
39607631
같은 제1저자의 인용 많은 논문 (3)
- Real-world sequential treatment patterns and outcomes in the new era of immunotherapy for advanced gastric cancer in Japan.
- Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study).
- Real-world evaluation of interstitial lung disease/pneumonitis in patients treated with trastuzumab deruxtecan for HER2-positive advanced or recurrent gastric cancer: a postmarketing surveillance study in Japan.